News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Closing For Pernix Therapeutics, Inc. (PTX) Transaction To Acquire Treximet® Tablets For Migraine From GlaxoSmithKline (GSK) Delayed



8/4/2014 10:56:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MORRISTOWN, N.J.--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet® (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES